Suppr超能文献

先天性糖基化障碍、半乳糖血症和果糖血症中的血浆溶酶体酶活性。

Plasma lysosomal enzyme activities in congenital disorders of glycosylation, galactosemia and fructosemia.

作者信息

Michelakakis Helen, Moraitou Marina, Mavridou Irene, Dimitriou Evangelia

机构信息

Department of Enzymology and Cellular Function, Institute of Child Health, Athens, Greece.

出版信息

Clin Chim Acta. 2009 Mar;401(1-2):81-3. doi: 10.1016/j.cca.2008.11.024. Epub 2008 Dec 3.

Abstract

BACKGROUND

Variable increases in the plasma activity of different lysosomal enzymes have been reported in patients with congenital disorders of glycosylation (CDG). In particular, elevated plasma aspartylglucosaminidase activity (AGA) has been found in the majority of CDG type I patients. We report on the plasma activity of AGA and other lysosomal enzymes in patients with different types of primary and secondary CDG defects.

METHODS

AGA, alpha-mannosidase, beta-mannosidase and beta-hexosaminidase activities were assayed in the plasma of patients with CDGI (4CDGIa, 4CDGIx) and CDGIIx (5, all with a combined N- and O-glycosylation defect), classical galactosemia (GALT) (n=3) and hereditary fructose intolerance (HFI) (n=2).

RESULTS

Increased AGA and beta-hexosaminidase activities were found in all and 7/8 of the GDGI patients respectively. All enzymic activities were normal in the CDGIIx patients. Elevated AGA and beta-hexosaminidase activity was also seen in GALT and HFI patients before treatment, when transferrin isoelectric focusing (TfIEF) patterns were also abnormal.

CONCLUSIONS

Increased AGA plasma activity, although a consistent finding in CDGI patients, is not specific to this group of disorders since it is also observed in untreated cases of GALT and HFI. Furthermore, plasma AGA activity cannot serve as a marker for CDGII disorders. In conjunction with TfIEF it could be used in the follow up of GALT and HFI patients.

摘要

背景

据报道,先天性糖基化障碍(CDG)患者血浆中不同溶酶体酶的活性会出现不同程度的升高。特别是,大多数I型CDG患者血浆中天冬氨酰葡糖胺酶(AGA)活性升高。我们报告了不同类型原发性和继发性CDG缺陷患者的AGA及其他溶酶体酶的血浆活性。

方法

检测了I型CDG(4例I型CDGa、4例I型CDGx)和II型CDGx(5例,均存在N-糖基化和O-糖基化联合缺陷)、经典型半乳糖血症(GALT)(n =3)和遗传性果糖不耐受症(HFI)(n =2)患者血浆中的AGA、α-甘露糖苷酶、β-甘露糖苷酶和β-己糖胺酶活性。

结果

所有I型CDG患者及8例中的7例分别出现AGA和β-己糖胺酶活性升高。II型CDGx患者的所有酶活性均正常。在治疗前,GALT和HFI患者的转铁蛋白等电聚焦(TfIEF)模式异常时,也观察到AGA和β-己糖胺酶活性升高。

结论

虽然I型CDG患者中一致发现血浆AGA活性升高,但这并非该组疾病所特有,因为在未经治疗的GALT和HFI病例中也观察到了这一现象。此外,血浆AGA活性不能作为II型CDG疾病的标志物。结合TfIEF,它可用于GALT和HFI患者的随访。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验